VANDA PHARMACEUTICALS INC. Accumulated Other Comprehensive Income
VANDA PHARMACEUTICALS INC. (VNDA) had Accumulated Other Comprehensive Income of $38.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $38.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $212.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $629.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $540.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $38.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $212.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $629.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $540.00K 10-Q · filed 2025-10-30 |
| 2025-06-30 | $396.00K 10-Q · filed 2025-07-31 |
| 2025-03-31 | $383.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $74.00K 10-K · filed 2026-02-12 |
| 2024-09-30 | $702.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$330.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$383.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$30.00K 10-K · filed 2025-02-14 |
| 2023-09-30 | -$967.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$865.00K 10-Q · filed 2023-07-28 |
| 2023-03-31 | -$255.00K 10-Q · filed 2023-05-03 |
| 2022-12-31 | -$1.19M 10-K · filed 2024-02-08 |
| 2022-09-30 | -$1.49M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$1.43M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$1.33M 10-Q · filed 2022-05-06 |
| 2021-12-31 | -$175.00K 10-K · filed 2023-02-09 |
| 2021-09-30 | $111.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $103.00K 10-Q · filed 2021-07-29 |
| 2021-03-31 | $192.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $239.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $379.00K 10-Q · filed 2020-10-29 |
| 2020-06-30 | $596.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $781.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $249.00K 10-K · filed 2021-02-11 |
| 2019-09-30 | $211.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $386.00K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $135.00K 10-Q · filed 2019-05-03 |
| 2018-12-31 | $1.00K 10-K · filed 2020-02-26 |
| 2018-09-30 | $70.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $79.00K 10-Q · filed 2018-08-02 |
| 2018-03-31 | -$28.00K 10-Q · filed 2018-05-02 |
| 2017-12-31 | -$34.00K 10-K · filed 2019-02-19 |
| 2017-09-30 | $73.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $11.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $50.00K 10-Q · filed 2017-05-03 |
| 2016-12-31 | $58.00K 10-K · filed 2018-02-15 |
| 2016-09-30 | $142.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $124.00K 10-Q · filed 2016-07-28 |
| 2016-03-31 | $92.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $39.00K 10-K · filed 2017-02-17 |
| 2015-09-30 | $37.00K 10-Q · filed 2015-11-04 |
| 2015-06-30 | $27.00K 10-Q · filed 2015-07-31 |
| 2015-03-31 | $27.00K 10-Q · filed 2015-05-07 |
| 2014-12-31 | $16.00K 10-K · filed 2016-02-12 |
| 2014-09-30 | $4.00K 10-Q · filed 2014-10-27 |
| 2013-12-31 | $21.00K 10-K · filed 2015-03-13 |
| 2012-12-31 | $10.00K 10-Q · filed 2013-05-10 |
| 2012-09-30 | $23.00K 10-Q · filed 2012-11-08 |
| 2012-06-30 | $5.00K 10-Q · filed 2012-08-03 |
| 2012-03-31 | $27.00K 10-Q · filed 2012-05-09 |
| 2011-12-31 | $21.00K 10-K · filed 2013-02-26 |
| 2011-09-30 | $44.00K 10-Q · filed 2011-11-07 |
| 2011-06-30 | $85.00K 10-Q · filed 2011-08-05 |
| 2010-12-31 | $2.00K 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |